N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia-A Double-Blind, Randomized, Placebo-Controlled Trial

Biological Psychiatry

Volumn 64, Issue 5, 2008, Pages 361-368

  Berk, Michael ^a,b,c   Copolov, David ^a,d   Dean, Olivia ^a,b   Lu, Kristy ^b   Jeavons, Sue ^e,f   Schapkaitz, Ian ^b   Anderson Hunt, Murray ^b   Judd, Fiona ^e   Katz, Fiona ^f   Katz, Paul ^f   Ording Jespersen, Sean ^f   Little, John ^g   Conus, Philippe ^h   Cuenod, Michel ^h   Do, Kim Q ^h   Bush, Ashley I ^a,b,i  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e Monash University and Bendigo Health Care Group   (Australia)

^f Southwestern Health   (Australia)

^g Queen Elizabeth Centre   (Australia)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adjunct therapy; clinical trials; glutathione; n acetyl cysteine; schizophrenia

Indexed keywords

ACETYLCYSTEINE; ARIPIPRAZOLE; CLOZAPINE; GLUTATHIONE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; BRAIN LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EFFECT SIZE; EVALUATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA;

EID: 48749112603     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.03.004     Document Type: Article

References (44)

1. Meister A., and Anderson M.E. Glutathione. Annu Rev Biochem 52 (1983) 711-760
2. Do K.Q., Trabensinger M.K., Lauer C.J., Dydak U., Hell D., Holsboer F., et al. Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 12 (2000) 3721-3728
3. Yao J.K., Leonard S., and Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 22 (2006) 83-93
4. Tosic M., Ott J., Barral S., Bovet P., Deppen P., Gheorghita F., et al. Schizophrenia and oxidative stress: Glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 79 (2006) 586-592
5. Gysin R., Kraftsik R., Sandell J., Bovet P., Chappuis C., Conus P., et al. Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. Proc Natl Acad Sci U S A 104 (2007) 16621-16626
6. Smythies J.R. Oxidative reactions and schizophrenia: A review-discussion. Schizophr Res 24 (1997) 357-364
7. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52 (1995) 998-1007
8. Castagne V., Rougemont M., Cuenod M., and Do K.Q. Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: Relevance to schizophrenia. Neurobiol Dis 15 (2004) 93-105
9. Steullet P., Neijt H.C., Cuenod M., and Do K.Q. Synpatic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia. Neuroscience 137 (2006) 807-819
10. Sjodin K., Nilsson E., Hallberg A., and Tunek A. Metabolism of N-acetyl-L-cysteine. Some structural requirements for the deacetylation and consequences for the oral bioavailability. Biochem Pharmacol 38 (1989) 3981-3985
11. Borgstrom L., and Kagedal B. Dose dependent pharmacokinetics of N-acetylcysteine after oral doing to man. Biopharm Drug Dispos 11 (1990) 131-136
12. Holdiness M.R. Clinical pharmokinetics of N-acetylcysteine. Clin Pharmacokinet 20 (1991) 123-134
13. Farr S.A., Poon H.F., Dogrukol-Ak D., Drake J., Banks W.A., Eyerman E., et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 84 (2003) 1173-1183
14. Aydin S., Ozaras R., Uzun H., Belce A., Uslu E., Tahan V., et al. N-acetylcysteine reduced the effect of ethanol on antioxidant system in rat plasma and brain tissue. Tohoku J Exp Med 198 (2002) 71-77
15. Tandon S.K., Singh S., Prasad S., Khandekar K., Dwivedi V.K., Chatterjee M., et al. Reversal of cadmium induced oxidative stress by chelating agent, antioxidant or their combination in rat. Toxicol Lett 145 (2003) 211-217
16. Ercal N., Treeratphan P., Hammond T.C., Matthews R.H., Grannemann N.H., and Spitz D.R. In vivo indices of oxidative stress in lead-exposed C57BL/6 mice are reduced by treatment with meso-2,3-dimercaptosuccinic acid or N-acetylcysteine. Free Radic Biol Med 21 (1996) 157-161
17. Flora S.J. Arsenic-induced oxidative stress and its reversibility following combined administration of N-acetylcysteine and meso 2,3-dimercaptosuccinic acid in rats. Clin Exp Pharmacol Physiol 26 (1999) 865-869
18. Kamboj A., Kiran R., and Sandhir R. Carbofuran-induced neurochemical and neurobehavioral alterations in rats: Attenuation by N-acetylcysteine. Exp Brain Res 170 (2006) 567-575
19. Andreassen O.A., Dedeoglu A., Klivenyi P., Beal M.F., and Bush A.I. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 11 (2000) 2491-2493
20. Ferrari G., Yan C.Y., and Greene L.A. N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells. J Neurosci 15 (1995) 2857-2866
21. Koppal T., Drake J., and Butterfield D.A. In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. Biochim Biophys Acta 1453 (1999) 407-411
22. Mayer M., and Noble M. N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci U S A 91 (1994) 7496-7500
23. Staal F.J., Anderson M.T., and Herzenberg L.A. Redox regulation of activation of NF-kappa B transcription factor complex: Effects of N-acetylcysteine. Meth Enzymol 252 (1995) 168-174
24. Beller E.M., Gebski V., and Keech A.C. Randomisation in clinical trials. Med J Aust 177 (2002) 565-567
25. Demedts M., Behr J., Buhl R., Costabel U., Dekhuijzen R., Jansen H.M., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353 (2005) 2229-2242
26. Van Schooten F.J., Besaratinia A., De Flora S., D'Agostini F., Izzotti A., Camoirano A., et al. Effects of oral administration of N-acetyl-L-cysteine: A multi-biomarker study in smokers. Cancer Epidemiol Biomarkers Prev 11 (2002) 167-175
27. Behr J., Degenkolb B., Krombach F., and Vogelmeier C. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: Effects of N-acetylcysteine. Eur Respir J 19 (2002) 906-911
28. Adair J.C., Knoefel J.E., and Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 57 (2001) 1515-1517
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Association, Washington, DC
30. Schmidt L.E., and Dalhoff K. Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning. Br J Clin Pharmacol 51 (2001) 87-91
31. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. [published online ahead of print November 14, 2007]. Neuropsychopharmacology (2007)
32. Rijcken C.A., Monster T.B., Brouwers J.R., and de Jong-van den Berg L.T. Chlorpromazine equivalents versus defined daily doses: How to compare antipsychotic drug doses?. J Clin Psychopharmacol 23 (2003) 657-659
33. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64 (2003) 663-667
34. Ng F., Berk M., Dean O., and Bush A.I. Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. [published online ahead of print January 21, 2008]. Int J Neuropsychopharmacol (2008)
35. Dakhale G., Khanzode S., Khanzode S., Saoji A., Khobragade L., and Turankar A. Oxidative damage and schizophrenia: The potential benefit by atypical antipsychotics. Neuropsychobiology 49 (2004) 205-209
36. Gama C.S., Salvador M., Andreazza A.C., Kapczinski F., and Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: A study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 512-515
37. Harvey B.H., Joubert C., du Preez J.L., and Berk M. Effect of chronic N-acetylcysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum. Neurochem Res 33 (2008) 508-517
38. Behrens M.M., Ali S.S., Dao D.N., Lucero J., Shekhtman G., Quick K.L., et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 318 (2007) 1645-1647
39. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 62 (2000) 649-671
40. Baker D.A., Madayag A., Kristiansen L.V., Meador-Woodruff J.H., Haroutunian V., and Raju I. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. [published online ahead of print August 29, 2007]. Neuropsychopharmacology (2007)
41. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., and Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 62 (2003) 195-204
42. Dakhale G.N., Khanzode S.D., Khanzode S.S., and Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 182 (2005) 494-498
43. Dringen R., and Hirrlinger J. Glutathione pathways in the brain. Biol Chem 384 (2003) 505-516
44. Do K.Q., Trabensinger M.K., Lauer C.J., Dydak U., Hell D., Holsboer F., et al. Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 12 (2000) 3721-3728